文献速递认知障碍与痴呆

额颞叶变性的社会与经济负担

The social and economic burden of frontotemporal degeneration.
PubMed 文献 · Neurology · 2017-10-04

该研究通过250项网络调查评估了额颞叶变性(FTD)主要照护者的社会经济负担,674名照护者完成调查。FTD患者年均总成本为119654美元(直接成本47916美元,间接成本71737美元),约为阿尔茨海默病报告成本的近2倍;诊断后家庭收入从75000-99000美元降至50000-59999美元。

要点

  • FTD年均总成本119654美元,近AD的2倍,间接成本占主导。
  • 65岁以上、晚期及bvFTD患者直接成本更高;65岁以下和男性间接成本更高。
  • 诊断后12个月内家庭收入显著下降,源于工作日损失和提前退出劳动力。

核心结论

  • FTD的经济负担巨大,计入生产力相关成本后,每患者成本高于AD报告值。

研究设计与样本

  • 对956名FTD主要照护者进行250项网络调查,674人(70.5%)完成全部调查。

主要发现

  • 直接成本47916美元,间接成本71737美元,年均总成本119654美元(2016年美元)。
  • 65岁及以上、晚期疾病和bvFTD与更高直接成本相关。
  • 65岁以下和男性与更高间接成本相关。
  • 诊断前12个月家庭收入75000-99000美元,诊断后12个月降至50000-59999美元。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the socioeconomic burden of frontotemporal degeneration (FTD) compared to previously published data for Alzheimer disease (AD). METHODS: A 250-item internet survey was administered to primary caregivers of patients with behavioral-variant FTD (bvFTD), primary progressive aphasia, FTD with motor neuron disease, corticobasal syndrome, or progressive supranuclear palsy. The survey included validated scales for disease staging, behavior, activities of daily living, caregiver burden, and health economics, as well as investigator-designed questions to capture patient and caregiver experience with FTD. RESULTS: The entire survey was completed by 674 of 956 respondents (70.5%). Direct costs (2016 US dollars) equaled $47,916 and indirect costs $71,737, for a total annual per-patient cost of $119,654, nearly 2 times higher than reported costs for AD. Patients ≥65 years of age, with later stages of disease, and with bvFTD correlated with higher direct costs, while patients <65 years of age and men were associated with higher indirect costs. An FTD diagnosis produced a mean decrease in household income from $75,000 to $99,000 12 months before diagnosis to $50,000 to $59,999 12 months after diagnosis, resulting from lost days of work and early departure from the workforce. CONCLUSIONS: The economic burden of FTD is substantial. Counting productivity-related costs, per-patient costs for FTD appear to be greater than per-patient costs reported for AD. There is a need for biomarkers for accurate and timely diagnosis, effective treatments, and services to reduce this socioeconomic burden.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Galvin JE, Howard DH, Denny SS, et al. The social and economic burden of frontotemporal degeneration. Neurology. 2017. PMID: 28978658. doi:10.1212/WNL.0000000000004614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。